Pregabalin
Product Images NDC 45865-126

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 45865-126). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Medsource Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pregabalin Capsules 100 mg (Pdp 126)

This is a medication description for Pregabalin, which is a generic version of the brand-name drug Lyrica. The medication comes in the form of capsules that contain 100mg of the active ingredient. The manufacturer is ScieGen PHARM. INC. The medication may cause dizziness and should be taken as directed by a physician, typically a certain number of capsules per day. The rest of the text is not-readable gibberish.*

FDA Label Image

Figure 1 (Pregabalin Fig01)

FDA Label Image

Figure 2 (Pregabalin Fig02)

FDA Label Image

Figure 3 (Pregabalin Fig03)

The text appears to be a table showing different medications and the number of patients who improved while taking them, as well as the percentage of improvement in pain from baseline. The medications listed are Pregatalin 300, Pregabain 160, and Pregabalin 75. However, the table is difficult to interpret due to the unclear formatting and non-English characters.*

FDA Label Image

Figure 4 (Pregabalin Fig04)

FDA Label Image

Figure 5 (Pregabalin Fig05)

The text appears to be presenting data from a study of three treatments for pain: Fregabalin 100 mg, Pregataiin 80 mg, and placebo. The data includes the number of patients that improved with each treatment and a graph showing the percent improvement in pain compared to baseline.*

FDA Label Image

Figure 6 (Pregabalin Fig06)

FDA Label Image

Figure 7 (Pregabalin Fig07)

FDA Label Image

Figure 9 (Pregabalin Fig08)

The text describes a graph that shows the percentage of patients who improved after taking different doses of Pregabalin daily. The doses mentioned are 300mg and 450mg. There is also a comparison with a placebo group. The graph displays the percent improvement in pain from the baseline on the X-axis and percent of patients improved on the Y-axis.*

FDA Label Image

Figure 10 (Pregabalin Fig09)

This appears to be a table showing estimated percentage of subjects without LTR (likely a measure or characteristic being studied) for a medication called "Progabain" and for the control group, "Placebo". The table shows percentages ranging from 0% to 100% at different time points indicated along the bottom row (e.g. 20, 40, 80 days, etc.). Without any context or further information about the study, it is impossible to provide additional details or insights.*

FDA Label Image

Figure 11 (Pregabalin Fig10)

FDA Label Image

Figure 12 (Pregabalin Fig11)

This table shows the percentage of subjects who improved from baseline to week 16 of a clinical study for Pregabalin and Placebo. The values range from 100 to 280, with increments of 10 percent.*

FDA Label Image

Cockcroft And Gault Equation (Pregabalin Formula)

This appears to be a formula for calculating creatinine clearance (CLCT) using a patient's age, weight, and serum creatinine level. The formula is: CLCT = [140 - age (years)] x weight (kg) x e (x 0.85 for female patients) / 72 x serum creatinine (mg/dL). However, some of the characters in the formula are illegible, so the exact values and units for the variables cannot be determined.*

FDA Label Image

Chemical Structure (Pregabalin Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.